Amphastar Pharmaceuticals Total Current Liabilities 2012-2024 | AMPH

Amphastar Pharmaceuticals total current liabilities from 2012 to 2024. Total current liabilities can be defined as the sum of all liabilities classified as current for having maturities of less than one year.
Amphastar Pharmaceuticals Annual Total Current Liabilities
(Millions of US $)
2023 $225
2022 $95
2021 $104
2020 $112
2019 $90
2018 $107
2017 $67
2016 $61
2015 $60
2014 $63
2013 $65
2012 $60
2011 $
2009 $127
Amphastar Pharmaceuticals Quarterly Total Current Liabilities
(Millions of US $)
2024-09-30 $159
2024-06-30 $137
2024-03-31 $255
2023-12-31 $225
2023-09-30 $258
2023-06-30 $251
2023-03-31 $106
2022-12-31 $95
2022-09-30 $102
2022-06-30 $104
2022-03-31 $114
2021-12-31 $104
2021-09-30 $98
2021-06-30 $125
2021-03-31 $127
2020-12-31 $112
2020-09-30 $97
2020-06-30 $93
2020-03-31 $83
2019-12-31 $90
2019-09-30 $87
2019-06-30 $101
2019-03-31 $112
2018-12-31 $107
2018-09-30 $97
2018-06-30 $88
2018-03-31 $73
2017-12-31 $67
2017-09-30 $57
2017-06-30 $64
2017-03-31 $73
2016-12-31 $61
2016-09-30 $61
2016-06-30 $66
2016-03-31 $65
2015-12-31 $60
2015-09-30 $71
2015-06-30 $69
2015-03-31 $72
2014-12-31 $63
2014-09-30 $63
2014-06-30 $56
2014-03-31 $73
2013-12-31 $65
2013-09-30
2013-06-30
2013-03-31
2012-12-31 $60
2012-09-30
2012-06-30
2012-03-31
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.335B $0.644B
Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. It focuses primarily on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company products include Enoxaparin Sodium Injection; Amphadase; Cortrosyn for Injection; and prefilled disposable emergency syringes for crash cart use. Amphastar Pharmaceuticals, Inc. is headquartered in Rancho Cucamonga, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.679B 6.46
Dr Reddy's Laboratories (RDY) India $12.521B 23.96
BridgeBio Pharma (BBIO) United States $4.911B 0.00
Bausch Health Cos (BHC) Canada $3.439B 2.49
Supernus Pharmaceuticals (SUPN) United States $2.022B 27.53
Taysha Gene Therapies (TSHA) United States $0.334B 54.33
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.104B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00